Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.47 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286235 | 0.84 | LTA4H (0.44) | LTA4HSLC6A3GPR142ALDH1A1RAB9A | |
| Eprodisate SCHEMBL27535860 | 0.83 | LTA4H (0.42) | LTA4HSLC6A3GPR142RAB9ASMN1; SMN2 | |
| SCHEMBL29991111 | 0.78 | FYN (0.46) | LTA4HSLC6A3FYN | |
| SCHEMBL7992030 | 0.77 | GPR142 (0.49) | SLC6A3GPR142TDP1 | |
| SCHEMBL29131248 | 0.77 | NPC1 (0.46) | SLC6A3GPR142ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL7493474 | 0.75 | SLC6A4 (0.41) | LTA4HSLC6A3GPR142ALDH1A1RAB9A | |
| SCHEMBL29131241 | 0.74 | SLC6A3 (0.41) | SLC6A3GPR142RAB9ASMN1; SMN2SLC6A2 | |
| SCHEMBL29131243 | 0.74 | SLC6A3 (0.41) | SLC6A3GPR142RAB9ASMN1; SMN2SLC6A2 | |
| SCHEMBL6031397 | 0.73 | GAA (0.53) | GPR142SMN1; SMN2 | |
| SCHEMBL6001756 | 0.73 | SLC6A3 (0.41) | SLC6A3RAB9ASMN1; SMN2L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101980706-A | Combination of a dithiazole salt or precursor thereof and artemisinin or a derivative thereof for the treatment of acute malaria | SANOFI AVENTIS | 2011-02-23 | — | — | CN | claimed |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| CN-101980706-B | Combination of salts of Chinese pulsatilla thiazolicola or precursors thereof and artemisinin or derivatives thereof for the treatment of acute malaria | SANOFI AVENTIS | 2013-11-27 | — | — | CN | disclosed |
| CN-101980706-A | Combination of a dithiazole salt or precursor thereof and artemisinin or a derivative thereof for the treatment of acute malaria | SANOFI AVENTIS | 2011-02-23 | — | — | CN | disclosed |
| CN-101528691-A | Matrix metalloproteinase inhibitors | RANBAXY LAB LTD (IN) | 2009-09-09 | — | — | CN | disclosed |
| EP-1196371-A1 | QUATERNARY BIS-AMMONIUM SALT PRECURSORS AND THEIR USES AS PRODRUGS HAVING AN ANTIPARASITIC ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005742-A1 | QUATERNARY BIS-AMMONIUM SALT PRECURSORS AND THEIR USES AS PRODRUGS HAVING AN ANTIPARASITIC ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | MB, MYOC, PDE6A | LTA4H 450/4885SLC6A3 2449/4885CALM1 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.